About Terns Pharmaceutical
Terns Pharmaceutical is a company based in San Mateo (United States) founded in 2017 was acquired by Merck in March 2026. Terns Pharmaceutical has raised $207.7 million across 3 funding rounds from investors including Merck, Lilly and Orbimed. The company has 46 employees as of December 31, 2022. Terns Pharmaceutical offers products and services including Oncology Drugs and Obesity Treatments. Terns Pharmaceutical operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, NGM Biopharmaceuticals and argenx, among others.
- Headquarter San Mateo, United States
- Employees 46 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Terns Pharmaceuticals, Inc.
-
Annual Revenue
$1 M (USD)0as on Dec 31, 2021
-
Net Profit
-$88.85 M (USD)2as on Dec 31, 2024
-
EBITDA
-$101.87 M (USD)1as on Dec 31, 2024
-
Total Equity Funding
$207.7 M (USD)
in 3 rounds
-
Latest Funding Round
$97.7 M (USD), Series C
Jan 05, 2021
-
Investors
Merck
& 8 more
-
Employee Count
46
as on Dec 31, 2022
-
Acquired by
Merck
(Mar 25, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Terns Pharmaceutical
Terns Pharmaceutical is a publicly listed company on the NASDAQ with ticker symbol TERN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Terns Pharmaceutical
Terns Pharmaceutical offers a comprehensive portfolio of products and services, including Oncology Drugs and Obesity Treatments.
Small-molecule candidates for treating cancer and related diseases
Products aimed at managing obesity through innovative development
People of Terns Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of Terns Pharmaceutical
Terns Pharmaceutical has successfully raised a total of $207.7M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $97.7 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Terns Pharmaceutical
Terns Pharmaceutical has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Lilly and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Private equity investments are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Terns Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Terns Pharmaceutical
Investment portfolio details for Terns Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Terns Pharmaceutical
Detailed financials for Terns Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Terns Pharmaceutical Comparisons
Peer comparison for Terns Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Terns Pharmaceutical
Terns Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, NGM Biopharmaceuticals and argenx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Terns Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Terns Pharmaceutical
Complete news archive for Terns Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Terns Pharmaceutical
Terns Pharmaceutical was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Terns Pharmaceutical is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Terns Pharmaceutical is a funded company, having raised a total of $207.7M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Terns Pharmaceutical is 46.
Annual revenue of Terns Pharmaceutical is $1M as on Dec 31, 2021.
Terns Pharmaceuticals was founded in 2017 and is headquartered in San Mateo, United States. Focus is placed on developing treatments for liver conditions including nonalcoholic steatohepatitis and nonalcoholic fatty liver disease, alongside oncology applications. Pipeline candidates encompass TERN-101 as a Farnesoid X Receptor agonist, TERN-201, TERN-501, and a GLP-1R agonist, all targeted at addressing unmet needs in these therapeutic areas. Operations center on advancing clinical-stage assets in the biopharmaceutical sector.
Terns Pharmaceutical's top competitors include Moderna, argenx and Forge Biologics.
Terns Pharmaceutical offers Oncology Drugs and Obesity Treatments.
Yes, Terns Pharmaceutical is publicly traded on NASDAQ under the ticker symbol TERN.
Terns Pharmaceutical has 9 investors. Key investors include Merck, Lilly, Orbimed, Lilly Asia Ventures, and Vivo Capital.
The ticker symbol of Terns Pharmaceutical is TERN on NASDAQ.